Multidisciplinary Treatment of Obesity Prior to in Vitro Fertilization: Impact on Global Reproductive Outcomes (PRO-FIV Study)

Sponsor
Hospital Clinic of Barcelona (Other)
Overall Status
Unknown status
CT.gov ID
NCT03395067
Collaborator
(none)
104
1
2
34.1
3

Study Details

Study Description

Brief Summary

The aim of the present study is to evaluate the impact of a multidisciplinary treatment of obesity prior to IVF on global reproductive outcomes and maternofetal metabolic and cardiovascular risk factors.

This is a randomized controlled trial in obese infertile women before starting an IVF cycle. The intervention is based on a structured multidisciplinary program in support groups, which includes diet, physical activity and psychological therapy. IVF will be started immediately after this therapy. Patients included in the control group will start an IVF cycle immediately after the randomization. The results of this study may allow the identification of patients who would benefit from obesity treatment, so as to establish appropriate preventive and therapeutic strategies and to reduce the maternal obesity impact in future generations.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Intervention group
N/A

Detailed Description

The aim of the present study is to evaluate the impact of a multidisciplinary treatment of obesity prior to IVF on global reproductive outcomes and maternofetal metabolic and cardiovascular risk factors.

This is a randomized controlled trial in obese infertile women (body mass index ≥30 kg/m2) before starting an IVF cycle. In the intervention group, the aim is a weight loss of at least 10% in a 16-week period of treatment based on a multidisciplinary approach and support groups, which includes diet, physical activity and psychological therapy. IVF will be started immediately after this period. Patients included in the control group will start an IVF cycle immediately after the randomization. The results of this study may allow the identification of patients who would benefit from obesity treatment, so as to establish appropriate preventive and therapeutic strategies and to reduce the maternal obesity impact in future generations.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
104 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trial including 2 arms: intervention group and control group.Randomized controlled trial including 2 arms: intervention group and control group.
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Multidisciplinary Treatment of Obesity Prior to In Vitro Fertilization: Impact on Global Reproductive Outcomes
Anticipated Study Start Date :
Jan 28, 2018
Anticipated Primary Completion Date :
Dec 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Lifestyle counseling

Behavioral: Intervention group
Lifestyle counseling coupled with psychotherapeutical intervention

No Intervention: Control group

Outcome Measures

Primary Outcome Measures

  1. live birth rate of a healthy baby in a non-complicated pregnancy [10 months after starting the IVF treatment]

    live birth rate in a pregnancy without major complications: gestational diabetes, hypertensive disorders, preterm delivery, congenital anomalies, stillbirth, neonatal death, shoulder dystocia, maternal venous thromboembolism, fetal growth abnormal outcomes (macrosomia, large for gestational age, intrauterine growth restriction)

Secondary Outcome Measures

  1. anthropometric parameters: weight (kilograms) [4 months after starting the intervention]

    weight change during intervention, measured in kilograms

  2. anthropometric parameters: body mass index - BMI (kilograms/metro2) [4 months after starting the intervention]

    BMI change during intervention, measured as kilograms/metro2

  3. anthropometric parameters: abdominal circumference (centimeters) [4 months after starting the intervention]

    abdominal circumference change during intervention measured in centimeters

  4. hormonal parameters: antimullerian hormone (AMH) [2 years (simultaneous analysis of all the biological samples)]

    AMH serum levels before the intervention (intervention group) and before the IVF (2 arms)

  5. hormonal parameters: insulin [2 years (simultaneous analysis of all the biological samples)]

    insulin serum levels before the intervention (intervention group) and before the IVF (2 arms)

  6. hormonal parameters: leptin [2 years (simultaneous analysis of all the biological samples)]

    leptin serum levels before the intervention (intervention group) and before the IVF (2 arms)

  7. hormonal parameters: adiponectin [2 years (simultaneous analysis of all the biological samples)]

    adiponectin serum levels before the intervention (intervention group) and before the IVF (2 arms)

  8. hormonal parameters: ghrelin [2 years (simultaneous analysis of all the biological samples)]

    ghrelin serum levels before the intervention (intervention group) and before the IVF (2 arms)

  9. IVF outcomes: cycle cancellation rate [3 months after starting IVF cycle]

    cycle cancellation rate: cancelled cycles/ initiated cycles

  10. IVF outcomes: gonadotropin doses (UI) [3 months after starting IVF cycle]

    total gonadotropin doses used in the IVF stimulation protocol

  11. IVF outcomes: number of oocytes [3 months after starting IVF cycle]

    number of oocytes retrieved

  12. IVF outcomes: number of embryos [3 months after starting IVF cycle]

    total number of embryos obtained in 2 pronuclear stage

  13. IVF outcomes: number of good quality embryos [3 months after starting IVF cycle]

    number of good quality embryos (type A and B) obtained in the cleavage stage

  14. IVF outcomes: clinical pregnancy rate [3 months after starting IVF cycle]

    clinical pregnancy rate: clinical pregnancies/started cycles

  15. IVF outcomes: miscarriage rate [3 months after starting IVF cycle]

    miscarriage rate: miscarriages/clinical pregnancies

  16. fetal ultrasound [26-30 weeks after confirmation of pregnancy]

    fetal ultrasound and Doppler parameters at 28-32 weeks of gestation. All parameters are measured according to the current guidelines and reported as quantitative measurements.

  17. postpartum anthropometric outcomes: maternal abdominal circumference (centimeters) [12 months after the delivery]

    Maternal abdominal circumference in centimeters 1 month and 12 months after the delivery

  18. postpartum anthropometric outcomes: maternal weight (kilograms) [12 months after the delivery]

    Maternal weight in kilograms 1 month and 12 months after the delivery

  19. postpartum anthropometric outcomes: neonatal weight (grams) [12 months after the delivery]

    neonatal weight in grams 1 month and 12 months after the delivery

  20. postpartum anthropometric outcomes: neonatal height (centimeters) [12 months after the delivery]

    neonatal height in centimeters 1 month and 12 months after the delivery

  21. postpartum anthropometric outcomes: neonatal skin fold measurements (millimeters) [12 months after the delivery]

    neonatal skin fold measurements in millimeters 1 month and 12 months after the delivery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Obese infertile patients (body mass index ≥ 30 Kg/m2) prior to an in vitro fertilization cycle
Exclusion Criteria:
  • Pathological conditions: diabetes type I, Cushing syndrome, premature ovarian failure, uncontrolled thyroidal dysfunction, hepatic and/or renal dysfunction, antiphospholipid syndrome, medical condition that contraindicate ovarian stimulation and/or pregnancy

  • Simultaneous practice of another strategy to lose weight

  • Physical conditions limiting exercise training

  • Patients unable to understand spanish language or to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Clínic de Barcelona Barcelona Spain 08036

Sponsors and Collaborators

  • Hospital Clinic of Barcelona

Investigators

  • Principal Investigator: Gemma Casals, Hospital Clinic of Barcelona

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gemma Casals i Soler, Principal Investigator, Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT03395067
Other Study ID Numbers:
  • HCB/2017/0730
First Posted:
Jan 10, 2018
Last Update Posted:
Jan 30, 2018
Last Verified:
Jan 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gemma Casals i Soler, Principal Investigator, Hospital Clinic of Barcelona
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 30, 2018